Company: APM
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001213900-25-037669
Chunk: 121

Company: Aptorum Group Ltd
Filing Date: 2025-04-30
Form: 20-F
Item: Item 4
Chunk 121
---
571,422)
was granted in February 2023, and altogether the SACT-1 patent portfolio has four (4) active national phase patent applications
all over the world.

Paths Dx

Infectious disease diagnostic
standard of care (SOC) often involves techniques that are slow (e. g., bacterial culturing takes several days) or expensive (e. g., current
pathogen diagnostic sequencing solutions are not comprehensive, are expensive, and often inaccessible to physicians). Although infectious
disease diagnosis capabilities have been improving in recent years, there are still issues with the public health capacity to control
infectious disease threats.

Infectious disease diagnostic
standard of care (SOC) does not necessarily provide the physician a comprehensive diagnosis or report. Most point of care diagnostic solutions,
while rapid, screen only for a single pathogen and only focus on common and widespread pathogens (e. g., HIV). Thus, for infectious disease
patients in developed nations that present with an uncommon, novel or emerging pathogen threat, diagnosis is often slow (2-5 days) and
inconclusive leaving time for pathogen spread and increased patient suffering and/or death.

PathsDxTest is
a rapid infectious disease diagnostic test that we believe will be potentially able to identify all pathogens in a patient’s sample,
both known and unknown, by employing Next Generation Sequencing (NGS). The goal of PathsDxTest is to cost-effectively return
a 99% accurate result within 24-48 hours. Our internal results show that, in principle, PathsDxTest can identify pathogens
such as viruses (e. g. COVID-19/SARS-CoV-2) or any other known or emerging infectious disease event in one test (e. g., DNA or RNA-based
pathogens). With these properties, PathsDxTest is expected to track the infectome landscape (e. g., tracking mutations), rapidly
identify antibiotic resistant microbials in the process, and be more affordable than current NGS-based diagnostic platforms, which will
make it a superior product to those currently on the market.

Preliminary data from our
internal studies, which have not been verified or confirmed by third parties, presented below demonstrate additional points of innovation
and proof of concept feasibility data.

Case Study #1We examined a bio
banked blood sample from a patient with a diagnosed Hepatitis B infection (Figure 6). Our technology successfully detected the presence
of Hepatitis B, as well as additional pathogens